Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Health Care Rationing | 4 | 2021 | 437 | 2.100 |
Why?
|
Leukemia, Myeloid, Acute | 7 | 2023 | 3523 | 1.020 |
Why?
|
Leukemia | 2 | 2024 | 1508 | 1.000 |
Why?
|
Neoplasms | 12 | 2024 | 21672 | 0.990 |
Why?
|
Hematologic Neoplasms | 3 | 2021 | 1831 | 0.960 |
Why?
|
Translating | 1 | 2022 | 144 | 0.800 |
Why?
|
Pharmaceutical Preparations | 2 | 2020 | 1071 | 0.770 |
Why?
|
Pharmacists | 2 | 2020 | 247 | 0.730 |
Why?
|
Social Justice | 1 | 2024 | 456 | 0.680 |
Why?
|
Resource Allocation | 1 | 2021 | 341 | 0.660 |
Why?
|
Decision Making, Organizational | 1 | 2019 | 139 | 0.660 |
Why?
|
Hepatitis B | 1 | 2024 | 695 | 0.650 |
Why?
|
Climate Change | 2 | 2023 | 418 | 0.640 |
Why?
|
Medical Oncology | 5 | 2023 | 2265 | 0.630 |
Why?
|
Pharmacy Service, Hospital | 1 | 2019 | 133 | 0.630 |
Why?
|
State Government | 1 | 2021 | 372 | 0.620 |
Why?
|
Pharmacy | 1 | 2019 | 91 | 0.600 |
Why?
|
Standard of Care | 1 | 2021 | 564 | 0.580 |
Why?
|
Antineoplastic Agents | 4 | 2022 | 13668 | 0.560 |
Why?
|
Radiation Oncology | 1 | 2022 | 555 | 0.550 |
Why?
|
Artificial Intelligence | 3 | 2024 | 2213 | 0.520 |
Why?
|
Compassionate Use Trials | 1 | 2015 | 46 | 0.510 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 260 | 0.500 |
Why?
|
Neoplasm, Residual | 2 | 2019 | 972 | 0.490 |
Why?
|
Ethics Committees, Clinical | 1 | 2014 | 56 | 0.470 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 689 | 0.460 |
Why?
|
Environmental Monitoring | 1 | 2020 | 1414 | 0.460 |
Why?
|
Patient Preference | 1 | 2020 | 887 | 0.440 |
Why?
|
Ethics, Medical | 2 | 2015 | 792 | 0.420 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2019 | 941 | 0.380 |
Why?
|
Patient Selection | 2 | 2020 | 4216 | 0.370 |
Why?
|
Health Policy | 1 | 2022 | 2661 | 0.360 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2015 | 428 | 0.350 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2019 | 3598 | 0.340 |
Why?
|
Epidemics | 1 | 2015 | 523 | 0.330 |
Why?
|
Clinical Protocols | 1 | 2014 | 1462 | 0.310 |
Why?
|
Decision Making | 2 | 2020 | 3888 | 0.290 |
Why?
|
Vaccines | 1 | 2015 | 822 | 0.270 |
Why?
|
Myelodysplastic Syndromes | 3 | 2021 | 1352 | 0.260 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 3923 | 0.250 |
Why?
|
Azacitidine | 2 | 2017 | 347 | 0.250 |
Why?
|
Humans | 37 | 2024 | 744220 | 0.230 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7281 | 0.230 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2023 | 288 | 0.230 |
Why?
|
Opioid-Related Disorders | 1 | 2018 | 2065 | 0.230 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2017 | 640 | 0.220 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5529 | 0.210 |
Why?
|
Antiviral Agents | 1 | 2015 | 2987 | 0.210 |
Why?
|
Bilirubin | 1 | 2024 | 425 | 0.210 |
Why?
|
Ethics Consultation | 1 | 2022 | 52 | 0.210 |
Why?
|
Analgesics, Opioid | 1 | 2018 | 3674 | 0.210 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5138 | 0.200 |
Why?
|
Physicians | 1 | 2020 | 4564 | 0.200 |
Why?
|
United States | 8 | 2023 | 69867 | 0.190 |
Why?
|
Cross-Sectional Studies | 4 | 2024 | 25043 | 0.180 |
Why?
|
Patient Rights | 1 | 2021 | 126 | 0.180 |
Why?
|
Environmental Health | 1 | 2022 | 278 | 0.180 |
Why?
|
Mutation | 4 | 2020 | 29784 | 0.180 |
Why?
|
Illinois | 1 | 2020 | 119 | 0.180 |
Why?
|
Vincristine | 1 | 2022 | 1036 | 0.180 |
Why?
|
Melanoma | 1 | 2018 | 5475 | 0.180 |
Why?
|
Hospital Bed Capacity | 1 | 2021 | 214 | 0.180 |
Why?
|
Pharmacies | 1 | 2021 | 150 | 0.170 |
Why?
|
Hospitals, University | 1 | 2020 | 571 | 0.160 |
Why?
|
Cancer Care Facilities | 1 | 2021 | 402 | 0.160 |
Why?
|
Health Priorities | 1 | 2021 | 380 | 0.150 |
Why?
|
HIV Infections | 1 | 2024 | 16718 | 0.150 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 933 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11493 | 0.150 |
Why?
|
Survival Rate | 3 | 2022 | 12781 | 0.150 |
Why?
|
Biological Specimen Banks | 1 | 2022 | 712 | 0.150 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2018 | 434 | 0.140 |
Why?
|
Erythrocyte Transfusion | 1 | 2021 | 565 | 0.140 |
Why?
|
Academic Medical Centers | 2 | 2019 | 2759 | 0.140 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 7908 | 0.130 |
Why?
|
Africa, Western | 1 | 2015 | 154 | 0.130 |
Why?
|
Health Services Misuse | 1 | 2016 | 243 | 0.120 |
Why?
|
Patient Care | 1 | 2020 | 640 | 0.120 |
Why?
|
Sulfonamides | 1 | 2023 | 1940 | 0.120 |
Why?
|
Minority Groups | 1 | 2021 | 1223 | 0.120 |
Why?
|
Acute Disease | 1 | 2024 | 7148 | 0.110 |
Why?
|
Health Care Surveys | 1 | 2020 | 2453 | 0.110 |
Why?
|
Anemia | 1 | 2021 | 1504 | 0.100 |
Why?
|
Health Services Research | 1 | 2019 | 1836 | 0.100 |
Why?
|
Guidelines as Topic | 1 | 2018 | 1404 | 0.100 |
Why?
|
Injections | 1 | 2014 | 840 | 0.090 |
Why?
|
Aged | 10 | 2023 | 163253 | 0.090 |
Why?
|
Advance Care Planning | 1 | 2018 | 662 | 0.090 |
Why?
|
World Health Organization | 1 | 2015 | 1318 | 0.080 |
Why?
|
Adult | 8 | 2023 | 214035 | 0.080 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 12355 | 0.080 |
Why?
|
Developing Countries | 1 | 2021 | 2814 | 0.080 |
Why?
|
Male | 13 | 2024 | 350027 | 0.080 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 4803 | 0.080 |
Why?
|
Myeloproliferative Disorders | 1 | 2014 | 605 | 0.080 |
Why?
|
Drug Industry | 1 | 2014 | 745 | 0.080 |
Why?
|
Retrospective Studies | 6 | 2023 | 77426 | 0.070 |
Why?
|
Survival Analysis | 2 | 2018 | 10250 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10949 | 0.070 |
Why?
|
Bone Marrow | 1 | 2016 | 2944 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2948 | 0.070 |
Why?
|
Germ-Line Mutation | 1 | 2014 | 1787 | 0.070 |
Why?
|
Palliative Care | 1 | 2021 | 3490 | 0.070 |
Why?
|
Aged, 80 and over | 6 | 2021 | 57768 | 0.070 |
Why?
|
Middle Aged | 9 | 2021 | 213367 | 0.060 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2011 | 1380 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3746 | 0.060 |
Why?
|
Female | 12 | 2021 | 380197 | 0.060 |
Why?
|
Intensive Care Units | 1 | 2016 | 3680 | 0.060 |
Why?
|
Prognosis | 3 | 2020 | 29050 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5319 | 0.050 |
Why?
|
Transplantation, Homologous | 2 | 2020 | 4776 | 0.050 |
Why?
|
Quality of Life | 1 | 2021 | 12805 | 0.040 |
Why?
|
Internship and Residency | 1 | 2020 | 5787 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2020 | 63119 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2014 | 5853 | 0.040 |
Why?
|
Young Adult | 3 | 2020 | 56436 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2023 | 6893 | 0.040 |
Why?
|
Remission Induction | 1 | 2023 | 2389 | 0.040 |
Why?
|
Chicago | 1 | 2018 | 240 | 0.040 |
Why?
|
Algorithms | 1 | 2018 | 13885 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2019 | 802 | 0.040 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2020 | 5442 | 0.040 |
Why?
|
Hospitalization | 1 | 2016 | 10262 | 0.040 |
Why?
|
5-Methylcytosine | 1 | 2016 | 154 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 17449 | 0.030 |
Why?
|
Comorbidity | 2 | 2017 | 10387 | 0.020 |
Why?
|
Age Factors | 2 | 2020 | 18367 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2458 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8321 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2014 | 1676 | 0.020 |
Why?
|
Pedigree | 1 | 2014 | 4648 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6535 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11007 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4188 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8343 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8628 | 0.020 |
Why?
|
Prospective Studies | 2 | 2021 | 53280 | 0.020 |
Why?
|
Terminal Care | 1 | 2016 | 1694 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14726 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15538 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 5169 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13280 | 0.010 |
Why?
|
Risk Factors | 1 | 2016 | 72280 | 0.010 |
Why?
|
Adolescent | 1 | 2017 | 85759 | 0.010 |
Why?
|
Concepts
(145)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(33)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_